Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and aromatase inhibitors’ effect on endothelial function and heart disease (Abstracts S5-06 and S5-07).
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
